Understanding Reimbursement Issues in Maryland

A Guide for Health Care Providers and Practice Administration

Example EYLEA® (aflibercept) Injection Claim Issues and Applicable State Provisions

Prior Authorization	Prompt Payment	Request for Additional Information	Filing Deadlines	Provider Appeals
Issue: Plan delays prior authorization. Example scenario: Patient is diagnosed and meets medical necessity criteria for EYLEA injections. Provider submits a request for prior authorization. Plan has not made a decision.	Issue: Plan delays timely payment pending medical necessity determination. Example scenario: Patient is diagnosed and meets medical necessity criteria for EYLEA injections. Provider submits a claim for EYLEA reimbursement, but 31 days later, claim is still pending medical necessity determination.	Issue: Subsequent request for additional information. Example scenario: Provider submits a claim for EYLEA reimbursement, but 31 days later, Plan indicates payment of claim is pending receipt of additional information.	Issue: Claim is past the filing deadline. Example scenario: Provider timely submits an EYLEA claim. Plan denies the claim for being past the filing deadline.	Issue: Provider appeals. Example scenario: Provider wants to challenge Plan's denial or reduction of an EYLEA claim.
Maryland Insurance Code Section 15-10b-06 states	Maryland Insurance Code Section 15-1005 states	Maryland Insurance Code Section 15-1005 states	Maryland Insurance Code Section 15-1005 states	Maryland Administrative Code Chapter 31.10.18 states
A utilization review agent must make all initial determinations on whether to authorize a nonemergency course of treatment for a patient within 2 working days after receipt of the information necessary to make the determination. Maryland Insurance Code Section 15-854 states Effective January 1, 2020: If a provider indicates that a prescription drug is needed to treat a chronic condition, a payer may not request a reauthorization for a period of 1 year or for the standard course of treatment for the chronic condition.	Plan must do any of the following within 30 days of receiving a claim for reimbursement: Pay the claim Deny the claim and provide reasons for the denial Notify provider of additional information necessary to determine whether all or part of the claim will be reimbursed	Plan must send notice that the claim is not clean and the specific additional information necessary for the claim to be considered a clean claim.† †Claim with no defect or impropriety (eg, lack of required substantiating documentation) or circumstance requiring special treatment that prevents timely payment from being made on the claim.	Plan must allow provider a minimum of 180 days from the date a covered service is rendered to submit a claim for reimbursement for the service. NOTE: This provision sets forth minimum contractual standards. Provider should check contract for specific requirements.	Internal grievance: Plan must render a final decision: Within 30 working days after the filing date on a grievance involving a prospective denial in a nonemergency case Within 45 working days after the filing date on a grievance involving a retrospective denial Maryland Administrative Code Chapter 31.10.19 states External review: With certain exceptions, an independent external review must be completed within 45 days.
	Maryland Insurance Code Section 15-1009(b) states			
	Subject to exceptions, if prior authorization has been obtained, Plan cannot deny reimbursement to provider for the preauthorized or approved service.			

Complaints regarding these and other payer issues can be made to the Maryland Insurance Administration website.



Visit Navigating Payer Challenges.com for state-specific and federal legislation or contact your Reimbursement Business Manager (RBM) for more information



This material is provided for informational purposes only, is subject to change, and should not be construed as legal or medical advice. Use of this information to challenge or appeal a coverage or reimbursement delay and/or denial by a payer is the responsibility of the provider.

Reference: Data on file. Regeneron Pharmaceuticals, Inc.



This information is provided to you